ai-in-biotech
(5)
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.
Yasir Al-Wakeel
Yasir Al-Wakeel is a physician turned biotech operator who in September 2025 became CEO of Vesalius Therapeutics and a CEO-Partner at Flagship Pioneering. Trained as a doctor at Oxford with a theology degree from Cambridge, he spent a decade structuring more than $30 billion in life-science deals before running finance and strategy at companies like Merrimack, Neon Therapeutics and Kronos Bio. At Vesalius he is betting that many common diseases are actually clusters of genetically distinct conditions waiting to be redefined.
Francisco Leport
Francisco Leport is the co-founder and CEO of Gordian Biotechnology, a South San Francisco-based company pioneering high-throughput in vivo drug discovery for age-related diseases. Trained as a physicist at Stanford, Leport pivoted from particle physics and energy tech into biotech, driven by a lifelong fascination with longevity sparked by his mother's fruit fly research. Gordian's signature 'mosaic screening' platform uses gene therapy vectors and single-cell RNA sequencing to test hundreds of therapies simultaneously in single animal models, with an AI system called Pythia scoring results against human disease signatures - achieving 80% accuracy in predicting clinical outcomes. The company raised a $60M Series A in April 2024, backed by Founders Fund, Gigafund, and The Longevity Fund, and in early 2026 announced a research collaboration with Pfizer to accelerate obesity drug discovery.
Peyton Greenside
Peyton Greenside is the CEO and co-founder of BigHat Biosciences, a San Mateo-based biotech company she co-founded in 2019 with Mark DePristo. A pioneer of deep learning applied to life science, Greenside combined a PhD in Biomedical Informatics from Stanford, an MPhil from Cambridge, and a BA in Applied Math from Harvard into a singular mission: use machine learning and synthetic biology to design safer, more effective antibody therapeutics faster than anyone thought possible. BigHat's Milliner platform generates thousands of unique antibody designs per week, and the company has raised $174M in total funding with pharma partnerships spanning Amgen, Merck, AbbVie, Johnson & Johnson, and Eli Lilly.
Bryan Faust
Bryan Faust, PhD is an Investment Partner on the Bio + Health team at Andreessen Horowitz (a16z), where he backs seed and Series A companies at the intersection of biology and technology. A trained biophysicist with a PhD from UCSF, he published research in Nature, Science, and Cell before pivoting to venture—studying antibody-protein interactions, GPCR signaling, and COVID-19 nanobodies along the way. At a16z he has co-led investments in Stipple Bio, Tessera Labs, Gate Bioscience, and Formation Bio, and writes widely on AI in life sciences, biotech financing, and the coming era of programmable medicine. When he's not reading pitch decks, he's surfing, roasting coffee, or hunting down the perfect tacos al pastor.